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Abstract
The frequent oral shedding of herpes simplex virus type 1 (HSV-1) in the absence of clinical disease
suggests that symptomatic HSV-1 recurrences may be inhibited by the mucosal environment.
Indeed, saliva has been shown to contain substances with anti-HSV activity. In the current study,
we investigated the anti-HSV-1 activity of human lactoferrin (hLf) and lysozyme (hLz), two highly
cationic polypeptides of the mucosal innate defence system.
HLf blocked HSV-1 infection at multiple steps of the viral replication cycle, whereas lysozyme
displayed no anti-HSV-1 activity. Preincubation of HSV-1 virions and presence of hLf during or after
viral absorption period or for the entire HSV-1 infection cycle inhibited HSV-1 infection by
reducing both the plaque count and plaque size in a dose- and virus strain-dependent manner. Cell-
to-cell spread of wild-type HSV-1 and the strain gC-39, deleted of glycoprotein C, was dramatically
reduced, but the cell-to-cell spread of HSV-1 Rid1, harboring a mutated gD and thus unable to react
with the cellular HVEM receptor, remained unchanged. This suggests that the inhibition of cell-to-
cell spread is mediated by effects on gD or its cellular counterparts.
Our results show that the cationic nature is not a major determinant in the anti-HSV action of
mucosal innate cationic polypeptides, since whereas hLf inhibited HSV-1 infection efficiently, hLz
had no HSV-1 inhibiting activity. Our results show that in addition to inhibiting the adsorption and
post-attachment events of HSV-1 infection, hLf is also able to neutralize HSV-1 and that the
inhibition of cell-to-cell spread involves viral gD. These results suggest that Lf may have a significant
role in the modulation of HSV-1 infection in the oral cavity as well as in the genital mucosa, the
major sites of HSV-1 infection.
Findings
Oral mucosa is a common site of primary herpes simplex
virus type 1 (HSV-1) infection. After a primary infection in
the oral region, HSV-1 establishes latency in the trigemi-
nal ganglion. Subsequent reactivation of HSV-1 typically
results in asymptomatic shedding of virus into saliva, but
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only rarely in detectable intraoral lesions. Instead,
extraoral manifestations are frequent and affect 20–40%
of the HSV-seropositive population [1]. Thus the intraoral
environment may inhibit replication of HSV-1.
Lactoferrin (Lf) and lysozyme (Lz) are highly cationic
polypeptides with broad antimicrobial properties, abun-
dant in saliva, tears and cervicovaginal mucosal fluid. The
major inhibitory mechanism of Lf on HSV infection has
been suggested to occur by competitive binding of Lf to
negatively charged cell surface glycosaminoglycans
(GAGs) [2-4]. Furthermore, we have observed human Lf
(hLf) to inhibit post-attachment events in the HSV-1 rep-
lication including entry and cell-to-cell spread [5]. This
finding has been confirmed with both bovine and human
Lf [6,7]. Lactoferrin has also been suggested to affect the
HSV reactivation phenotype in the oral region [8].
The most characterized antimicrobial property of Lz is its
antibacterial muramidase activity, although some
enzyme-independent functions have been reported [9].
Observations on anti-HSV activity of Lz are contradictory
[10,11], but likely involve both enzymatic and cationic
properties of this enzyme [10].
In this study, we compared the anti-HSV activity of
human lactoferrin and lysozyme, and the roles of viral
glycoproteins gC and gD therein. We infected Vero cell
monolayers with HSV-1 in the presence or absence of
human milk-derived non-iron-saturated lactoferrin
(apoLf; L-0520, Sigma), iron-saturated lactoferrin (satLf;
L-3770, Sigma) or lysozyme (hLz; L-6394, Sigma). Virus
strains used were the wild-type (wt) HSV-1 strain KOS,
and the KOS-derived mutants Rid1 and gC-39. Rid1 has a
single amino acid substitution at position 27 of gD, a viral
glycoprotein essential for viral entry, that results in the
inability of this virus to use HVEM as an entry mediator
[12]. gC-39 lacks glycoprotein C, the major viral envelope
glycoprotein mediating initial attachment of HSV-1 to cell
surface GAGs [13].
First, confluent Vero cell monolayers on 24-well plates
were infected with 100 or 200 plaque-forming units (pfu)
of HSV-1 KOS, Rid1 or gC-39. For the infection studies,
fetal calf serum (FCS) concentration of MEM culture
medium with antibiotics was reduced from 10% to 1%
and medium was supplemented with 0–500 μg/ml of
apoLf or satLf, or 0–200 μg/ml of hLz at various time
points of infection (Figures 1, 2, 3, 4). Cultures with
medium without hLf and hLz served as negative controls.
Quadruplicate cultures were fixed with methanol 20
hours post-infection (h.p.i.), and infected cells were iden-
tified by immunoperoxidase staining (IPS) of viral pro-
teins with HRP-labelled polyclonal antibodies against
HSV-1 (P0175, DakoCytomation, Denmark, A/S) (modi-
fied from [14]). The number of plaques and plaque size
was determined by light microscopy.
Second, 50 pfu of HSV-1 KOS, Rid1, or gC-39 was
adsorbed to Vero cell monolayers in 12-well plates for 2 h
at 37°C. The inoculum was removed and fresh MEM
added, containing 1% FCS, antibiotics and 0.1% human
gammaglobulin supplemented with 0–500 μg/ml of
apoLf or satLf, or 0–200 μg/ml of hLz. After five days,
Lactoferrin but not lysozyme inhibited efficiently HSV-1 infection of Vero cells Figure 1
Lactoferrin but not lysozyme inhibited efficiently HSV-1 infection of Vero cells. Replication of wt HSV-1 and mutant 
viruses gC-39 and Rid1 in Vero cells with human non-iron-saturated Lf (apoLf), iron-saturated Lf (satLf) or lysozyme (hLz) 
present throughout the entire replication cycle. Lactoferrin and lysozyme were added to cell cultures 24 h prior to infection. 
The relative amount of viral plaques, in comparison to untreated cultures, is shown. Error bars represent standard deviations 
of three separate experiments. Statistical significance in the level of inhibition: * = p < 0.05, ** = p < 0.005, mutant viruses com-
pared to wt KOS. Only results with the highest concentration of hLz used are shown.
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Lactoferrin but not lysozyme neutralized HSV-1 Figure 2
Lactoferrin but not lysozyme neutralized HSV-1. Wt HSV-1 and mutant viruses gC-39 and Rid1 were incubated for 30 
min at 37°C with different concentrations of human non-iron-saturated Lf (apoLf), iron-saturated Lf (satLf) or lysozyme (hLz) 
prior to inoculation of Vero cell cultures. Preincubated virus/hLf mixtures were diluted 1:10 upon addition to the cell culture 
so that the inoculum contained 1–50 μg/ml of hLf. Therefore the observed inhibition could not have resulted from the hLf 
effect on the cells. The relative amount of viral plaques, in comparison to untreated cultures, is shown. Error bars represent 
standard deviations of three separate experiments. Statistical significance in the level of inhibition: * = p < 0.05, ** = p < 0.005, 
mutant viruses compared to wt KOS. Only results with the highest concentration of hLz used are shown.
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Pretreatment of cell cultures with lactoferrin but not lysozyme inhibited HSV-1 infection Figure 3
Pretreatment of cell cultures with lactoferrin but not lysozyme inhibited HSV-1 infection. Vero cell cultures were 
pretreated with human non-iron-saturated Lf (apoLf), iron-saturated Lf (satLf) or lysozyme (hLz) for 24 h prior to inoculation. 
To exclude lactoferrin and lysozyme effect on HSV-1 virion, these supplements were removed from the media by washing 
before inoculation of cultures with wt HSV-1 and mutant viruses gC-39 and Rid1. The relative amount of viral plaques, in com-
parison to untreated cultures, is shown. Error bars represent standard deviations of three separate experiments. Statistical sig-
nificance in the level of inhibition: * = p < 0.05, ** = p < 0.005, mutant viruses compared to wt KOS. Only results with the 
highest concentration of hLz used are shown.
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plaques formed by viruses were visualized by crystal violet
staining. Data were analysed by Student's two-tailed
paired t-test, and p-values less than 0.05 were considered
significant.
We found human lactoferrin (hLf) to interfere with the
progression of HSV-1 infection at multiple steps of the
viral replication cycle, whereas human lysozyme dis-
played no anti-HSV-1 activity. The degree of hLf iron-sat-
uration played little role in HSV-1 inhibition.
In the series of inhibition assays, cells were first main-
tained in hLf containing medium for 24 h before viral
inoculation and subsequently through the whole replica-
tion cycle (Figure 1). Already at a hLf concentration of 50–
100 μg/ml, HSV-1 replication was dramatically inhibited
independent of the degree of Lf iron-saturation. Both of
the mutant viruses, Rid1 and gC-39, were significantly
more resistant to hLf-mediated inhibition, indicating a
role for both gC and gD in the inhibition of viral replica-
tion.
A series of further experiments was carried out investigat-
ing hLf effect on the virion, the absorption and post-
absorption events in the replication cycle and cell-to-cell
spread. We found hLf to neutralize unbound wt HSV-1
with an IC50 of 100–250 μg/ml of hLf (Figure 2). HSV-1
mutants, gC-39 and Rid1, were significantly more resist-
ant to hLf-mediated neutralization, suggesting that neu-
tralization is mediated by effects of hLf on gC and gD or
their cellular counterparts. Moreover, preincubation of
gC-39 with apoLf unexpectedly enhanced infectivity in
low concentrations. This suggests that hLf binding to vir-
ion compensates for gC and facilitates formation of con-
tacts between virion bound hLf and cell surface Lf
receptors, as has been earlier also suggested to occur
between bovine Lf and gC-39 [4]. Instead, bLf has been
found unable to neutralize wt HSV-1 [3,6], although it has
been shown to bind to wt HSV-1 [2].
Wt HSV-1 and gC-39 were equally sensitive (IC50 250 μg/
ml) to hLf pretreatment of cells (Figure 3), suggesting that
this inhibition involves interactions participated by both
gC and gB, the other major glycoprotein mediating attach-
ment [15]. Cell surface GAGs have been shown to bind Lf
[4] and Lf anti-HSV-1 activity to decrease in the absence of
heparan sulphate [3] or viral gC when Lf was added to cul-
tures simultaneously with the virus [4]. These findings
strongly suggest a major role for inhibition of initial
attachment of both gB and gC to GAGs in the anti-HSV
action of Lf. In our study, pretreatment of cells inhibited
also Rid1 in higher hLf concentrations, suggesting that hLf
inhibition is not restricted only to HSV attachment to the
cell surface, but may also modulate gD-mediated viral
entry.
The sensitivity of post-attachment steps to hLf-mediated
inhibition was confirmed by the observed anti-HSV-1
activity of hLf added to cultures after viral adsorption (Fig-
ure 4). Of the studied viral strains, wt HSV-1 was the most
sensitive with IC50 of 250–500 μg/ml of hLf. Iron-satu-
rated form of hLf was slightly more effective. Rid1 infec-
Lactoferrin has inhibitory activity against HSV-1 infection also after viral adsorption Figure 4
Lactoferrin has inhibitory activity against HSV-1 infection also after viral adsorption. To study the lactoferrin 
effect on post-attachment events, wt HSV-1 and mutant viruses gC-39 and Rid1 were adsorbed to cells at 4°C, cultures were 
washed and human non-iron-saturated Lf (apoLf), iron-saturated Lf (satLf) or lysozyme (hLz) was added. The relative amount 
of viral plaques, in comparison to untreated cultures, is shown. Error bars represent standard deviations of three separate 
experiments. Statistical significance in the level of inhibition: * = p < 0.05, ** = p < 0.005, mutant viruses compared to wt KOS. 
Only results with the highest concentration of hLz used are shown.
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Lactoferrin inhibition of HSV-1 cell-to-cell spread is mediated by gD Figure 5
Lactoferrin inhibition of HSV-1 cell-to-cell spread is mediated by gD. HSV-1 KOS (a, d), gC-39 (b) and Rid1 (c) infec-
tion of Vero cells in the absence or presence of 500 μg/ml of human lactoferrin. Plaques formed by the infecting virus were vis-
ualized by crystal violet staining after 5 days of culture in the presence of human immunoglobulin (a-c) or by 
immunoperoxidase staining with polyclonal anti-HSV-1 antibody after 20 h of culture (d). Lactoferrin dramatically impaired the 
cell-to-cell spread of HSV-1 KOS and gC-39, but not of Rid1.
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tivity decreased 40–60% at a hLf concentration of 500 μg/
ml. Earlier, bLf has been shown not to affect differentially
on the entry of wt HSV-1 and Rid1 strains in a β-galactos-
idase assay [3]. Therefore, the observed gD-associated
post-attachment inhibition in our study may yield from Lf
interference with intracellular events in the replication
cycle or with the synthetized progeny viral components or
virions. Previously, both hLf [5] and bLf [6] have been
shown to reduce HSV-1 plaque number if added immedi-
ately after viral adsorption or 1 h after viral entry. This
inhibition has been suggested to result from Lf binding to
viral components intracellularly [6]. The N-terminal
region of Lf has been shown to carry a nuclear localization
signal [16] and to be able to translocate to the nucleus of
the cell [17]. The efficiency and mechanisms of Lf binding
and intake seem to be cell type-specific and to involve var-
ious receptors [3,7,17-19]. Therefore certain intracellular
antiviral effects of Lf may differ between cell types.
HLf was furthermore found to efficiently inhibit HSV-1
cell-to-cell spread as observed by crystal violet staining
five days post-infection and by IPS 20 h.p.i. (Figure 5.).
This observation corroborates with previous observations
[5-7]. In the current study, the inhibition was highly virus
strain-dependent. Cell-to-cell spread of wt and gC-39
viruses, but not of Rid1, was dramatically impaired at hLf
concentration of 500 μg/ml independently of the degree
of hLf iron-saturation (Figure 5). Some inhibition was
observed already at a concentration of 250 μg/ml, but not
in lower concentrations (data not shown). Cell-to-cell
spread is known to involve primarily gB and gE/gI and
also gD in certain cell types [20,21], but not gC directly
[22-24]. The susceptibility of gC-negative HSV-1 strain,
gC-39, to inhibition of cell-to-cell spread may result from
hLf interference with gB binding to heparan sulphate at
cell junctions [24]. More importantly, the fact that the
plaque-size of Rid1, with a modified gD, was not affected
by hLf, suggests that the observed inhibition is dependent
on gD or its cellular counterparts. Earlier, inhibition of
HSV-1 cell-to-cell spread by lactoferricin, a peptide gener-
ated from Lf by pepsin cleavage, has been shown to
involve chondroitin sulphate [7]. It is possible, that in
addition to inhibiting cell-to-cell spread of HSV-1, hLf
localized to the cell surface may also modulate the infec-
tivity of the released progeny virus.
In conclusion, we found hLf to interfere with the progres-
sion of HSV-1 infection at multiple steps of the viral rep-
lication cycle and with HSV-1 cell-to-cell spread in a dose-
and virus strain-dependent manner. Our studies show for
the first time that in addition to inhibiting the adsorption
and post-attachments steps of HSV-1 infection, hLf is also
able to neutralize HSV-1 and that the inhibition of cell-to-
cell spread is at least partly dependent on gD or its cellular
counterparts. The degree of hLf iron-saturation played lit-
tle role in the inhibition. HLz displayed no anti-HSV-1
activity, suggesting that cationic property alone has no sig-
nificant role in the anti-HSV activity of a polypeptide of
the mucosal innate defence system.
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